References:
1. Ghasemiyeh P, Borhani-Haghighi A,
Karimzadeh I, Mohammadi-Samani S, Vazin A, Safari A, et al. Major
Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and
Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke:
A Narrative Review. Therapeutics and Clinical Risk Management.
2020;16:595.
2. Ghasemiyeh P, Mohammadi-Samani S.
Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of
COVID-19? Trends in Pharmaceutical Sciences. 2020;6(2):65-6.
3. Ghasemiyeh P, Mohammadi-Samani S.
COVID-19 outbreak: Challenges in pharmacotherapy based on
pharmacokinetic and pharmacodynamic aspects of drug therapy in patients
with moderate to severe infection. Heart & Lung. 2020.
4. Park JJ, Decloedt EH, Rayner CR,
Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19:
complicated and often misinterpreted. The Lancet Global Health.
2020;8(10):e1249-e50.
5. Sterne JA, Murthy S, Diaz JV,
Slutsky AS, Villar J, Angus DC, et al. Association between
administration of systemic corticosteroids and mortality among
critically ill patients with COVID-19: a meta-analysis. Jama.
2020;324(13):1330-41.
6. Deftereos S, Giannopoulos G,
Vrachatis DA, Siasos G, Giotaki SG, Cleman M, et al. Colchicine as a
potent anti-inflammatory treatment in COVID-19: can we teach an old dog
new tricks? European Heart Journal-Cardiovascular Pharmacotherapy.
2020;6(4):255-.